4-(quinolin-4-yl)butan-1-amine | 120553-04-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-(quinolin-4-yl)butan-1-amine
• 英文别名: 4-Quinolin-4-yl-butylamine；4-(4-quinolinyl) butylamine；4-quinolin-4-ylbutan-1-amine
• CAS: 120553-04-0
• 化学式: C₁₃H₁₆N₂
• 分子量: 200.283
• InChiKey: SNTFNYVEKQPZFH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(quinolin-4-yl)butan-1-amine 在 甲醇 作用下， 以 水 、 乙腈 为溶剂， 反应 20.0h， 生成
  参考文献：
  名称：

  Synthesis and Antibacterial Activity of Ketolides (6-O-Methyl-3-oxoerythromycin Derivatives):  A New Class of Antibacterials Highly Potent Against Macrolide-Resistant and -Susceptible Respiratory Pathogens

  摘要：

  In the search for new antibiotics active against macrolide-resistant pneumococci and Haemophilus influenzae, we synthesized a new class of 3-oxo-6-O-methylerythromycin derivatives, so-called "ketolides". A keto function was introduced in position 3 after removal of L-cladinose, a sugar which has long been thought essential. Further modifications of the macrolactone backbone allowed us to obtain three different series of 9-oxime, 11,12-carbamate, and 11,12-hydrazonocarbamate ketolides. These compounds were found to be very active against penicillin/erythromycin-resistant pneumococci and noninducers of MLS(B) resistance. The 11,12-substituted ketolide 61 (HMR 3004) demonstrated a potent activity against multiresistant pneumococci associated with a well-balanced activity against all bacteria involved in respiratory infections including H. influenzae, Mycoplasma catarrhalis, group A streptococci, and atypical bacteria. In addition HMR 3004 displayed high therapeutic activity in animals infected by all major strains, irrespective of their resistance phenotype.

  DOI：

  10.1021/jm980240d
• 作为产物：
  描述：

  4-喹啉甲醛 在 palladium on activated charcoal potassium tert-butylate 、 氢气 、 一水合肼 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 为溶剂， 10.0 ℃ 、151.99 kPa 条件下， 反应 16.5h， 生成 4-(quinolin-4-yl)butan-1-amine
  参考文献：
  名称：

  Synthesis and Antibacterial Activity of Ketolides (6-O-Methyl-3-oxoerythromycin Derivatives):  A New Class of Antibacterials Highly Potent Against Macrolide-Resistant and -Susceptible Respiratory Pathogens

  摘要：

  In the search for new antibiotics active against macrolide-resistant pneumococci and Haemophilus influenzae, we synthesized a new class of 3-oxo-6-O-methylerythromycin derivatives, so-called "ketolides". A keto function was introduced in position 3 after removal of L-cladinose, a sugar which has long been thought essential. Further modifications of the macrolactone backbone allowed us to obtain three different series of 9-oxime, 11,12-carbamate, and 11,12-hydrazonocarbamate ketolides. These compounds were found to be very active against penicillin/erythromycin-resistant pneumococci and noninducers of MLS(B) resistance. The 11,12-substituted ketolide 61 (HMR 3004) demonstrated a potent activity against multiresistant pneumococci associated with a well-balanced activity against all bacteria involved in respiratory infections including H. influenzae, Mycoplasma catarrhalis, group A streptococci, and atypical bacteria. In addition HMR 3004 displayed high therapeutic activity in animals infected by all major strains, irrespective of their resistance phenotype.

  DOI：

  10.1021/jm980240d

文献信息

• 3,6-Bicyclolides
  申请人：Or Sun Yat

  公开号：US20060122128A1

  公开（公告）日：2006-06-08

  The present invention discloses compounds of formula (I) or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

  本发明公开了具有以下结构的化合物（I）或其药学上可接受的盐、酯或前药： 具有抗菌性能。本发明还涉及包含上述化合物的药物组合物，用于给需要抗生素治疗的受试者使用。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的细菌感染的方法。该发明还包括制备本发明化合物的方法。
• C12 Modified erythromycin macrolides and ketolides having antibacterial activity
  申请人：——

  公开号：US20030125266A1

  公开（公告）日：2003-07-03

  Antimicrobial macrolide compounds are provided having formulas II: 1 as well as pharmaceutically acceptable salts, esters or prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of the compounds.

  提供具有II:1式的抗微生物大环内酯化合物，以及其药用盐、酯或前药；包含这类化合物的药物组合物；通过给予这类化合物治疗细菌感染的方法；以及这类化合物的制备方法。
• Synthesis and antibacterial activity of novel C12 ethyl ketolides
  作者：Matthew T. Burger、Christy Hiebert、Mehran Seid、Daniel T. Chu、Lynn Barker、Mike Langhorne、Ribhi Shawar、Jolene Kidney、Manoj C. Desai、Jacob J. Plattner

  DOI：10.1016/j.bmc.2006.04.032

  日期：2006.8

  A novel series of C(12) ethyl erythromycin derivatives have been discovered which exhibit in vitro and in vivo potency against key respiratory pathogens, including those resistant to erythromycin. The C(12) modification involves replacing the natural C(12) methyl group in the erythromycin core with an ethyl group via chemical synthesis. From the C(12) ethyl macrolide core, a series of C(12) ethyl ketolides

  已经发现了一系列新的C（12）乙基红霉素衍生物，它们对关键的呼吸道病原体（包括对红霉素有抗性的病原体）表现出体外和体内效力。C（12）修改涉及通过化学合成用乙基取代红霉素核心中的天然C（12）甲基。从C（12）乙基大环内酯核心制备了一系列C（12）乙基酮缩酮，并测试了其对一组相关临床分离株的抗菌活性。无论是由于核糖体甲基化（erm）还是外排（mef），都发现了几种对大环内酯类敏感和耐药菌有效的化合物。特别是，C（12）乙基酮缩酮4k，4s，4q，4m和4t具有相似的抗菌谱，并且具有与商业酮内酯telithromycin相当的活性。
• Pyridyl substituted ketolide antibiotics
  申请人：Burger T. Matthew

  公开号：US20050009764A1

  公开（公告）日：2005-01-13

  Antimicrobial macrolide and ketolide compounds are provided having formulas XII: as well as pharmaceutically acceptable salts, esters or prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of the compounds.

  提供具有XII式的抗微生物大环内酯和酮内酯化合物，以及其药学上可接受的盐、酯或前药；包含这些化合物的药物组合物；通过给予这些化合物的途径治疗细菌感染的方法；以及制备这些化合物的过程。
• Anti-inflammatory guanidines, their preparation and compositions containing them
  申请人：SYNTEX (U.S.A.) INC.

  公开号：EP0188333A1

  公开（公告）日：1986-07-23

  A compound having the formula where Ar is naphthyl, biphenyl, quinolinyl, or substituted quinolinyl; X is oxygen or -NH-; Y is 2 to 8; R, is hydrogen, lower alkyl, phenyl, substituted phenyl; and R2 is alkyl, cycloalkyl, phenyl, substituted phenyl, or thiazolyl; and R3 is hydrogen, alkyl, cycloalkyl, phenyl, substituted phenyl, or thiazolyl, and the pharmaceutically acceptable salts thereof. Compounds of this general formula are useful as anti-inflammatories, and as anti-psoriatic agents.

  一种具有以下式子的化合物 Ar 是萘基、联苯基、喹啉基或取代的喹啉基；X 是氧或-NH-；Y 是 2 至 8；R，是氢、低级烷基、苯基、取代的苯基；R2 是烷基、环烷基、苯基、取代的苯基或噻唑基；R3 是氢、烷基、环烷基、苯基、取代的苯基或噻唑基，以及它们的药学上可接受的盐。 这种通式的化合物可用作消炎药和抗银屑病药。